WALTHAM, Mass.--(
BUSINESS WIRE
)--
Wolters Kluwer Health
and NEJM Group, publishers of the
New England Journal of Medicine
(NEJM), announced today that the new
NEJM AI
journal is now available on Wolters Kluwer’s
Ovid
®
medical research platform
.
NEJM AI
is a peer-reviewed monthly journal dedicated to exploring and integrating artificial intelligence (AI) in clinical medicine. Hospitals, government agencies, corporations, health systems and research institutions are able to access the journal organization wide through Ovid’s exclusive digital distribution of NEJM Group titles. Institutional access to
NEJM AI
builds upon a collaboration that enables online subscriptions to NEJM Group journals such as
New England Journal of Medicine
,
NEJM Evidence
,
NEJM Catalyst
and
NEJM Journal Watch,
where users can access subscriber content both on NEJM Group sites and on Ovid.
Bridging trusted research with the future of health
“With the proliferation of generative AI (GenAI) applications across industries, it’s clear that AI will have a profound impact on healthcare. Wolters Kluwer is at the forefront of bringing together expert solutions with trusted and authoritative research information,” said
Rafael Sidi
, Senior Vice President & General Manager of Health Research, Wolters Kluwer Health. “The medical field is at a pivotal juncture, with technology rapidly revolutionizing patient care to improve outcomes significantly.
NEJM AI
serves as a critical resource for clinicians, researchers, healthcare leaders, and policymakers globally, focusing on the transformative role of AI and machine learning.”
NEJM Group launched
NEJM AI
as a groundbreaking journal to advance the understanding and practical application of AI in medicine. The journal aims to link cutting-edge AI technology and practical medical applications that can one day transform patient care and healthcare outcomes. Led by renowned experts in medical AI, the global editorial leadership of
NEJM AI
brings together the best minds in medical AI research from various disciplines.
“
NEJM AI
will apply the same rigorous standards as our flagship journal to determine which AI tools are ready for use in medical settings,” said Isaac Kohane, M.D., Ph.D., Editor-in-Chief of
NEJM AI
. “We are not only publishing high-quality original research but aim to build a community of engagement that fosters open conversation among AI developers, clinicians, researchers, healthcare leaders and government officials.”
In addition to the new journal, NEJM Group offers “
NEJM AI Grand Rounds
,” a podcast that explores the deep issues at the intersection of artificial intelligence, machine learning, and medicine. The podcast will be complemented by community-building activities such as events and exclusive subscriber content looking at the forefront of marrying technological innovation with clinical expertise.
The Ovid research platform provides a vast library of thousands of full-text journal articles, eBooks, database resources, and workflow tools in a single, integrated solution. Wolters Kluwer products, services, and expert solutions are based on a foundation of trust, transparency, and responsibility – in line with the company’s values. Wolters Kluwer’s AI Principles, which guide the design, development and deployment of advanced technologies in helping customers solve their most complex problems, can be found
here
.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software, and services for professionals in healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG. We help our customers make critical decisions every day by providing
expert solutions
that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit
www.wolterskluwer.com
, follow us on
LinkedIn
,
Facebook
, and
YouTube
.